內地開始新冠疫苗加強針混打 可選智飛或康希諾疫苗
據《央視》引述國家衛健委疾控局副局長吳良有表示,內地新冠疫苗的加強免疫對奧密克戎株突破感染具有抑制效果。近日,經國務院聯防聯控機制批準,衛健委已開始部署序貫加強免疫接種。
序貫加強免疫策略實施後,凡全程接種國藥 (01099.HK)、科興公司(688136.SH)滅活疫苗或康希諾 (06185.HK)腺病毒載體疫苗滿六個月的18歲以上的目標人羣,可進行一劑次同源加強免疫,可選擇智飛生物(300122.SZ)旗下智飛龍科馬的重組蛋白疫苗,或康希諾腺病毒載體疫苗進行序貫加強免疫。對於目標人羣來說,同源加強免疫接種和序貫加強免疫選擇一種即可。
國務院聯防聯控機制科研攻關組疫苗研發專班專家組成員邵一鳴表示,爲做到有備無患,已部署疫苗研發單位開展奧密克戎變異株(omicron)疫苗研發,包括開展滅活疫苗研究,目前臨牀前研究已完成,進展較快的已向藥品審評中心提交臨牀試驗申報資料;開展針對omicron廣譜或多價重組蛋白疫苗研究,進展較快的也已向藥審中心滾動提交臨牀試驗申報資料;開展針對omicron腺病毒載體疫苗和核酸疫苗研發工作,進展較快的已經完成動物有效性和安全性實驗,正在準備申報臨牀試驗;以及有關機構已完成變異株疫苗研發和評價的指導原則,並點對點下發至疫苗研發單位。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.